THBS1 and chronic kidney disease: hVSMCs were treated for 24 h with TSP1 (0.2 to 10 nM) (Figure 1A) and IS (1–500 μM) (Figure 1B) at concentrations consistent with those observed in CKD patients [4,23], or plasma from patients with CKD (Figure 1C).